Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Botanix Pharmaceuticals Limited ( (AU:BOT) ).
Insignia Financial Ltd, on behalf of itself and its subsidiaries including IOOF and MLC entities, has notified Botanix Pharmaceuticals that it has ceased to be a substantial shareholder as of 12 March 2026. The change follows a series of on-market trades over recent months, with significant selling of BOT shares ultimately reducing Insignia’s holding below the substantial shareholder threshold, signalling a shift in the company’s institutional investor base that existing shareholders and market participants may monitor for its impact on liquidity and ownership concentration.
The most recent analyst rating on (AU:BOT) stock is a Buy with a A$1.00 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
More about Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Limited is an Australian-listed biotechnology company focused on developing and commercialising dermatology and other pharmaceutical therapies. Its shares trade on the ASX under the code BOT, attracting institutional and retail investors active in the healthcare and life sciences sector.
Average Trading Volume: 10,157,155
Technical Sentiment Signal: Sell
Current Market Cap: A$104.3M
Find detailed analytics on BOT stock on TipRanks’ Stock Analysis page.